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ABSTRACT
Objective The efﬁcacy of anti-tumour necrosis factors
(anti-TNFs) in patients with Crohn’s disease (CD) and
symptomatic small bowel stricture (SSBS) is controversial.
The aim of this study was to estimate the efﬁcacy of
adalimumab in these patients and to identify the factors
predicting success.
Design We performed a multicentre, prospective,
observational cohort study in patients with CD and
SSBS. The included patients underwent magnetic
resonance enterography at baseline and subsequently
received adalimumab. The primary endpoint was success
at week 24, deﬁned as adalimumab continuation
without prohibited treatment (corticosteroids after the
eight week following inclusion, other anti-TNFs),
endoscopic dilation or bowel resection. The baseline
factors independently associated with success were
identiﬁed using a logistic regression model, leading to a
simple prognostic score. Secondary endpoints were
prolonged success after week 24 (still on adalimumab,
without dilation nor surgery) and time to bowel resection
in the whole cohort.
Results From January 2010 to December 2011, 105
patients were screened and 97 were included. At week
24, 62/97 (64%) patients had achieved success. The
prognostic score deﬁned a good prognosis group with
43/49 successes, an intermediate prognosis group with
17/28 successes and a poor prognosis group with 1/16
successes. After a median follow-up time of 3.8 years,
45.7%±6.6% (proportion±SE) of patients who were in
success at week 24 (ie, 29% of the whole cohort) were
still in prolonged success at 4 years. Among the whole
cohort, 50.7%±5.3% of patients did not undergo bowel
resection 4 years after inclusion.
Conclusions A successful response to adalimumab
was observed in about two-thirds of CD patients with
SSBS and was prolonged in nearly half of them till the
end of follow-up. More than half of the patients were
free of surgery 4 years after treatment initiation.
Clinical Trial registration number NCT01183403;
Results.
INTRODUCTION
Crohn’s disease (CD) is an IBD that primarily
affects the terminal ileum and the colon.1 At the
time of disease onset, 81% of the patients have
inﬂammatory lesions, which become stricturing or
Signiﬁcance of this study
What is already known on this subject?
▸ Stricture is the most common complication in
small bowel Crohn’s disease (CD).
▸ Magnetic resonance enterography is useful to
diagnose and deﬁne both the extent and
functional impact of an intestinal stricture.
▸ The efﬁcacy of anti-tumour necrosis factors in
patients with CD and symptomatic small bowel
stricture is controversial.
What are the new ﬁndings?
▸ Adalimumab treatment is successful in 2/3 of
CD patients with symptomatic stricture at
week 24.
▸ Success is maintained in 1/3 (29%) of the
patients after a median follow-up time of
4 years among the whole cohort.
▸ More than half of the patients were free of
surgery 4 years after treatment initiation.
▸ We found an easy-to-use predictive score of
adalimumab success, based on clinical and
imaging factors.
How might it impact on clinical practice in
the foreseeable future?
▸ Our ﬁndings indicate that adalimumab is an
efﬁcient treatment in symptomatic small bowel
stricture associated with CD.
▸ Our score helps in making a factual decision
between medical or surgical treatment rather
than empirical.
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penetrating (deﬁned according to the Montreal classiﬁcation of
the lesions of CD2 in 19% within 90 days and in 50% within
20 years after the diagnosis, particularly when CD involves the
small bowel).3
Medical therapy may treat the inﬂammation, but endoscopic
treatment or surgery is often necessary to relieve small bowel
obstructions due to stricturing lesions.4 Anti-tumour necrosis
factor (anti-TNF) agents, such as inﬂiximab and adalimumab,
are efﬁcient drugs to induce and maintain remission in patients
with CD. However, conﬂicting data have been published about
the efﬁcacy of anti-TNFs in patients with stricturing CD.5 There
have been concerns regarding the use of anti-TNFs in patients
with established strictures. Indeed, several reports have sug-
gested that they increase the risk of intestinal obstruction.6–8
However, data from the TREAT registry and the ACCENT I
inﬂiximab maintenance trial did not show an increased risk of
obstruction in patients with or without intestinal stricture at
baseline.9 Moreover, other studies have found that anti-TNFs
could lead to a clinical response and stenosis reversal.10 11 No
deﬁnite conclusions can be drawn from these studies especially
due to their small sample size and retrospective design. It would
therefore be useful to have predictive markers of anti-TNFs efﬁ-
cacy in patients with intestinal strictures due to CD.
Magnetic resonance enterography (MRE) is useful to diag-
nose and deﬁne both the extent and functional impact of an
intestinal stricture, particularly when it concerns the small
bowel beyond the reach of the colonoscopy. It has a fair to good
sensitivity and high speciﬁcity for the diagnosis of small bowel
strictures.12 MRE may also be used to assess the degree of
inﬂammation and monitor the response to drug therapy.13–15
But whether it may predict the response to treatment has not
been evaluated in patients with CD who have intestinal
strictures.
In this study, our aims were to estimate the success rate of
adalimumab treatment in patients with CD and symptomatic
small bowel stricture and to identify factors predicting success.
METHODS
Study design and patients
Investigators from the Groupe d’Etudes Therapeutiques des
Affections Inﬂammatoires Digestives (GETAID) designed this
prospective, multicentre, open-label, postmarketing observa-
tional study. This study is registered on ClinicalTrials.gov, no.
NCT01183403.
To be included, patients had to be at least 18 years of age and
meet the following inclusion criteria: (a) a diagnosis of CD
according to the usual endoscopic, histological and imaging cri-
teria;1 (b) a single or several small bowel (duodenum, jejunum
or ileum) stricture(s) deﬁned according to Montreal classiﬁca-
tion as ‘occurrence of constant luminal narrowing with preste-
notic dilatation or obstructive signs/symptoms’ and identiﬁed by
radiological imaging or endoscopy; (c) obstructive symptoms
within the last eight weeks, except if only (i) mild to moderate
pain (postprandial abdominal pain or increased by diet, improv-
ing with abdominal noise), without nausea, vomiting and
abdominal cramps and (ii) diet restrictions without abdominal
pain; (d) failure/contraindications steroids and/or immunosup-
pressive agents and indications for anti-TNFs. We excluded
patients with surgical obstruction, intra-abdominal abscess, iso-
lated colonic stricture, change in the CD treatment during the
previous two months (azathioprine, 6-mercaptopurine, metho-
trexate), exposure to anti-TNFs within the last 12 months and
contraindications to MRE or anti-TNFs (positive chest radio-
graph for tuberculosis or a positive tuberculin skin test; bacterial
or viral infection; history of myocardial infarction, heart failure
or malignant disease in the past ﬁve years (except for basal-cell
skin cancer) and demyelinating neurological disease).
Procedures
MRE was performed at baseline in all patients on 1.5 or 3 T
systems. All MRE were performed after the oral administration
of 1200 mL of hyperosmotic water solution. Mandatory
sequences were breath-hold imaging performed in the coronal
plane using a T2-weighted single-shot turbo spin echo sequence
and a true Fast Imaging with Balanced Steady-state sequence
and (after intravenous administration of an antispasmodic agent)
a T1-weighted sequence before and 90 s, as well as 8 min after
an intravenous injection of gadolinium chelates. Ninety seconds
was considered to be the parenchymatous time and 8 min the
delayed enhancement time. All radiologists were invited to par-
ticipate in a speciﬁc meeting that included a systematic review of
all MRE criteria observed in patients with CD and a dedicated
digital video disc which included the items were distributed to
the participating centres. All the characteristic MRE criteria
described in the literature and known from clinical experiments
were noted by the local radiologist, but the results were not
transmitted to the clinician investigator except to conﬁrm the
stricture and the absence of contraindications to anti-TNFs
(abscess, tumour). Blind, internal or cutaneous ﬁstula were not
considered as contraindications to participate to the study pro-
vided that there was no associated abscess.
Adalimumab was administered subcutaneously at baseline
(week 0) at a dose of 160 mg, followed by 80 mg at week 2, and
then 40 mg every other week. Those who were under immuno-
suppressors were maintained for the study, and those who were
under steroids were tapered at the discretion of the clinician.
Patients were assessed using the Crohn’s Disease Activity
Index (CDAI), complete blood cell count and C reactive protein
(CRP) serum level within the three weeks before inclusion and
at weeks 8, 16 and 24 or at study withdrawal. Obstructive symp-
toms were graded using the Crohn’s Disease Obstructive Score
(CDOS), built by the authors’ clinical experience (YB, FC, and
Marc Lemann in memoriam) taking into account the character-
istics of obstructive pain (duration, intensity), associated signs
(nausea, vomiting), dietary restriction and hospitalisation,
graded on a scale of 0–6 (table 1). CDOS was measured at
weeks 0, 8, 16 and 24. The follow-up continued after week 24
or study withdrawal with recording of adalimumab withdrawal
for failure/intolerance and dilation for patients who were in
success at week 24, and for surgical resections for all patients.
Outcome measures
The primary endpoint was the success at week 24, deﬁned as
adalimumab continuation with all the following criteria: (a) no
use of a prohibited treatment (corticosteroids after the eight
week following inclusion, parenteral nutrition, other
anti-TNFs); (b) no endoscopic dilation; (c) no bowel surgery for
resection of small bowel stricture; (d) no severe adverse events
leading to adalimumab withdrawal and (e) no study withdrawal
whatever the reason. The secondary endpoints were the levels
and variations relative to baseline of the CDAI, CDOS and CRP
level at weeks 8, 16 and 24.
Predictive factors of success at week 24 measured at baseline
were looked for in order to develop a prognostic score of
success. All patients in success at week 24 were monitored until
the end of follow-up, and the time-to-adalimumab failure,
deﬁned as adalimumab withdrawal whatever the reason, or the
need for endoscopic dilation or surgical resection was noted. In
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addition, time to surgical resection was studied within the
whole cohort.
Statistical analysis
We calculated that a minimum of 80 patients was required to
detect an OR of success >2.0 or 4.0 with a power of 80%,
which was dependent on the adalimumab success rate being
between 50% and 70% and on the proportion of patients in the
good prognosis group being between 25% and 75%.
The distributions of patients and the disease characteristics at
enrolment are described as sample size, frequency and percent-
age or median and IQR. The baseline factors associated with
success were identiﬁed via a logistic regression model using
backward selection with the likelihood ratio test.16 All factors
with p values <0.20 in the univariate analysis were introduced
into the multivariate analysis. Continuous variables were cate-
gorised as quartiles, and adjacent categories were mixed when
success rates were close.17 18
Since coefﬁcients varied around 1.55 between 1.22 and 1.99,
a prognostic score with the same weight for all variables was
chosen for simplicity. According to the coefﬁcient estimates in
the multiple logistic regression model, we built a score in which
we attributed one point for each item. To assess the quality of
the prognostic score, patients were classiﬁed as having a poor,
intermediate or good prognosis according to two limits. The
proportions of patients correctly classiﬁed as success in the
good and in the good or intermediate prognostic groups, and as
failures in the poor prognosis group were estimated from 1000
bootstrapped samples of 97 patients (uniform selection with
replacement).19 The proportions of patients with prolonged
success as a function of the follow-up time and time to surgery
were calculated from week 0 using the Kaplan-Meier method.20
The closing date for the data analyses was 31 December 2014.
The statistical analyses were carried out using the SPSS V.19.1
statistical software program (SPSS, Chicago, Illinois, USA).
RESULTS
Patients
From January 2010 to December 2011, 105 patients from 20
GETAID centres from France and Belgium and 1 Italian centre
were screened. Eight patients were not included in the study
due to loss of follow-up (n=5), withdrawal of consent (n=2) or
presence of luminal abscess (n=1) before inclusion, and were
not analysed. Ninety-seven patients were included and analysed.
The baseline characteristics of the 97 included patients are
described in table 2. All 97 patients had a stricturing phenotype
(B2), according to the Montreal classiﬁcation of the lesions of
CD2 at inclusion, and 41 (42%) were treated with immunosup-
pressive agents (thiopurines, methotrexate) at the time of adali-
mumab initiation. The CDOS was >4 (ie, severe abdominal
pain for >1 week, mild to moderate abdominal pain every day
that was associated with nausea, vomiting, abdominal cramps
for >3 days or hospitalisation during the eight previous weeks)
in 59 (61%) cases. The locations of small intestinal strictures are
reported in online supplementary table 1S. There was a single
stricture in 69/97 (71%) patients, located in the ileum in 50/69
(72%). A previous endoscopic dilation had been performed in
16/97 (16%) of the patients. The baseline MRE features are
reported in table 3.
Primary and secondary endpoints
In total, 62 out of the 97 patients (64%) reached success at
week 24. In total, 35 patients failed to achieve success and were
switched to inﬂiximab, 8 patients underwent an intestinal resec-
tion, 2 patients had an endoscopic dilation, 10 patients had a
severe adverse effect leading to adalimumab discontinuation, 2
patients interrupted adalimumab treatment and 5 patients with-
drew from the study (four were lost to follow-up, one withdrew
consent). In eight cases, the failure was due to multiple reasons.
The values and variations of the CDOS, CDAI and CRP from
week 0 to week 24 and at the end of follow-up are shown in
online supplementary tables 3S and 4S. Among the 62 patients
in success at week 24, 88% had a CDAI <150. As shown in
online supplementary table 4S, CRP was signiﬁcantly associated
with response in univariate analysis, but not in multivariate ana-
lysis. Faecal calprotectin was measured in 44 (45%) patients at
baseline; its mean value (SD) was 408 (780).
Factors associated with treatment success and development
of a prognostic score
Online supplementary tables 4S and 5S summarise the clinical,
laboratory and imaging factors associated with success deter-
mined using a univariate analysis. Table 4 describes the prognos-
tic factors that were independently associated with success.
These were the use of immunosuppressive agents at the time of
Table 1 Crohn’s disease obstructive score
Grade OP intensity Days with OP (n) AS* Days with AS (n) Dietary restrictions Hospitalisation †
0 Nil No No
1 Mild to moderate‡ <4 No No No
2 Mild to moderate ≥4 No No No
3 Nil
Mild to moderate
Severe§
0
>0 and <56
1
No
Yes
Without consequence
<3
Yes
Without consequence No
4 Mild to moderate
Severe
>0 and <56
>1 and ≤7
Yes
Without consequence
≥3 Without consequence
Without consequence
No
5 Mild to moderate
Severe
56
>7
+AS
Without consequence
≥3 Without consequence
Without consequence
No
6 Without consequence Without consequence Without consequence Without consequence Yes
As built by the authors’ clinical experience (YB, FC and Marc Lemann in memoriam).
*Nausea and vomiting.
†Due to obstructive symptoms.
‡Pain occurring or increasing after a meal and improving with abdominal sounds and/or gas emission per the anus.
§Gas blockade with abdominal bloating.
AS, associated signs; OP, obstructive pain.
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adalimumab initiation, the presence of obstructive symptoms for
<5 weeks and a CDOS >4. The MRE items were a small bowel
stricture length of <12 cm, a maximal small bowel diameter
proximal to stricture(s) of 18–29 mm, a marked enhancement
on delayed phase and the absence of a ﬁstula. The numbers and
proportions of observed success for the three groups deﬁned by
the prognostic score are described in ﬁgure 1.
As estimated with the 95% CI from the bootstrap method,
the percentage of success among the 49 patients (range 35–67)
of the good prognostic group was 88.1 (84.3–91.4) and in the
77 patients (range 65–88) of the good or intermediate prognos-
tic groups was 77.7 (74.4–81.3). The percentage of failure
(non-response) among the 16 patients (range 5–28) in the poor
prognostic group was 94.4 (90.9–100.0). Based on these results,
patients with a score of two points or fewer were considered to
be unlikely to respond to adalimumab, while those with a score
of four points or more were considered to be likely to respond
to adalimumab, and those with a score of three points were in
between.
Long-term outcome
The median±SE follow-up time was 3.8±0.1 years. Figure 2
shows the long-term follow-up of the 62 patients who had
reached success with adalimumab at week 24. Thirty-three fail-
ures were observed and the proportion±SE of patients with
prolonged success (still on adalimumab, without dilation and
without surgery) was 45.7±6.6% at 4 years (11 patients still at
risk), that is, 29% of the whole cohort. Online supplementary
ﬁgure 1S shows the time-to-intestinal resection from inclusion
in the whole sample. 56.6%±5.0% and 78.3%±4.2% achieved
success and were surgery-free at week 52, respectively (ﬁgure 2
and online supplementary ﬁgure 1S). Forty-six patients were
operated on and 50.7%±5.3% of the patients had not been
operated 4 years after inclusion (21 patients still at risk). Among
patients who were in success at week 24, 21 intestinal resections
were subsequently performed and 64.9%±6.6% of the patients
had not been operated 4 years after inclusion (18 patients still
at risk).
Table 2 Baseline characteristics of the 97 patients with Crohn’s
disease and symptomatic small bowel stricture
Characteristics
n, frequency (%)
or median (IQR)
Male 44 (45)
Age (years) 36 (29–46)
Time since diagnosis (years) 8.8 (3.4–14.9)
Crohn’s disease phenotype at inclusion (Montreal classification)*
L1 (ileal disease) 58 (60)
L2 (colonic disease) 3 (3)
L3 (ileocolonic disease) 36 (37)
B2 (stricturing disease) 97 (100)
p† 19 (20)
Previous intestinal resection 43 (44)
Previous treatment with infliximab 7 (7)
Smoking history
Never 38 (39)
Current 42 (43)
Previous 17 (18)
Concomitant drug(s) at the time of inclusion
5-aminosalicylates 15 (15)
Budesonide ≥9 mg/day 22 (23)
Steroids ≥20 mg/day 20 (21)
Thiopurines 40 (41)
Methotrexate 1 (1)
No treatment 21 (22)
Clinical activity (Crohn’s Disease Activity Index >150) 58 (60)
C reactive protein (mg/dL) (n=92) 5.0 (2.0–11.8)
Description of the obstructive symptoms
Onset delay (weeks) 16 (6–48)
Evaluation of obstructive score on a seven-grade score‡
3 7 (7)
4 31 (32)
5 37 (38)
6 22 (23)
*Satsangi et al.2
†Perianal disease modifier added to B when concomitant perianal disease is present.
‡See table 1 for descriptions of the grades.
Table 3 Baseline magnetic resonance enterography features of
the 97 patients with Crohn’s disease and symptomatic small bowel
stricture(s) (maximal or more severe characteristic across strictures,
except if otherwise indicated)
Characteristics
n, frequency (%)
or median (IQR)
Maximum wall thickness (mm) 8 (7–10)
Stricture(s) length (mm)* 15 (7–25)
Degree of enhancement
Parenchymatous phase
At least mild to moderate 94 (97)
Severe 57 (59)
Delayed phase†
At least mild to moderate 91 (98)
Severe 53 (57)
Pattern of enhancement
Parenchymatous phase (90 s after gadolinium injection)
Homogeneous (>70%) 46 (47)
Layered (>70%) 52 (54)
Mixed pattern 10 (10)
Delayed phase (8 min after gadolinium injection)
Homogeneous 58 (62)
Layered 33 (35)
Mixed pattern 7 (8)
T2 wall hypersignal 61 (63)
Deep ulceration 26 (27)
Inflammatory change of mesenteric fat
Blurred wall at least 36 (37)
Mass or phlegmon without abscess 4 (4)
Luminal diameter in the segment proximal to the
narrowing (mm)
25 (18–29)
Luminal diameter in the most narrowed segment (mm) 2 (1–3)
Comb sign‡ 64 (66)
Fistula
Blind 17 (18)
Internal 7 (7)
Cutaneous 0 (0)
Abscess 0
Fibro-fatty proliferation 59 (61)
Lymph node§
Size >3 mm 58 (60)
Enhancement 54 (56)
*Sum of all strictures.
†n=93.
‡Hypervascular appearance of the mesentery.
§Maximum of perivascular and peri-intestinal lymph node.
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Safety
Serious adverse events were reported in 70/97 (72%) patients
(table 5). One patient had pancytopenia due to myelodysplasia
1 month after adalimumab initiation combined with azathiopr-
ine. The patient died at the age of 81 years, 12 months later in
spite of treatment withdrawal. No other death or serious oppor-
tunistic infections were reported. Three patients were pregnant
during the study and interrupted the treatment.
DISCUSSION
In this study, attempting to address a signiﬁcant clinical problem
in an area of unmet need, we showed that adalimumab treat-
ment was successful in 64% of CD patients with symptomatic
stricture at week 24. Success was maintained in 29% of the
whole cohort after a median follow-up time of nearly 4 years.
We also propose a predictive score of adalimumab success based
on clinical and imaging factors.
The treatment of patients with symptomatic small bowel stric-
ture is difﬁcult. The European Crohn’s Colitis Organization
Table 4 Estimated and final coefficients of the clinic-radiological prognostic score to be applied to the independent factors associated with a
high rate of success (n=93)
Factor/group with a high rate of success Coefficient estimate±SE OR of success estimate (95% CI) p Value Points, n
Immunosuppressive treatment/yes 1.23±0.62 3.42 (1.01–11.57) 0.040 1
Crohn’s disease obstructive score />4 1.25±0.65 3.48 (0.97–12.46) 0.046 1
Duration obstructive symptoms (weeks)/<5 1.79±0.81 6.00 (1.23–29.17) 0.016 1
Length of stricture <12 cm 1.80±0.67 6.04 (1.61–22.67) 0.0042 1
Maximal small bowel diameter proximal to stricture(s) (mm)/(18–29) 1.99±0.68 7.32 (1.92–27.85) 0.0013 1
Enhancement on delayed T1-weighted sequence/marked 1.78±0.66 5.92 (1.63–21.50) 0.0034 1
Fistula/no 1.55±0.76 4.72 (1.05 to 21.11) 0.035 1
Figure 1 The observed probability of success at week 24 in 93*
patients with Crohn’s disease and symptomatic small bowel stricture(s)
according to the clinicoradiological prognostic score†. *93 of 97
patients had a delayed T1weighted sequences; +for details see table 3.
Figure 2 Time to failure in the 62 patients with Crohn’s disease and symptomatic small bowel stricture(s) following the successful response to
adalimumab at week 24 (33 observed failures, median±SE follow-up time 3.8±0.1 years).
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consensus recommends that ‘localised ileocecal Crohn’s disease
with obstructive symptoms, but no signiﬁcant evidence of active
inﬂammation, should be treated by surgery’.21 However, the
lack of inﬂammation is difﬁcult to demonstrate by MRE and
does not predict the extent of ﬁbrosis, and inﬂammation and
ﬁbrosis are, in most cases, associated.22 23 Distinction between
inﬂammatory and ﬁbrotic strictures is a very important point.
Adler and colleagues, along with other groups, have showed
that the radiologist global impression of whether a stricture was
‘active’ or ‘inactive’ was not associated with the presence or
degree of ﬁbrosis.24 25 We have previously shown in a retro-
spective study which compared 53 MRE ﬁndings pathological
analysis of surgical specimens that higher was the inﬂammation,
higher was the ﬁbrosis.26 As other groups, we have examined
morphological and dynamic contrast-enhancement patterns that
correlate with intestinal ﬁbrosis in the resected specimens, but
were unable to establish thresholds for grading ﬁbrosis.27
Promising results have been recently published by Rimola
et al,22 suggesting that homogeneous enhancement at 7 min and
progression of enhancement over time at MRE are strongly cor-
related with ﬁbrosis. Before considering them in clinical prac-
tice, these parameters need to be validated prospectively.23
The present study was designed to evaluate the efﬁcacy of
adalimumab in patients with symptomatic small bowel stricture
and to identify clinical and imaging factors predicting its
success. To evaluate the success, we used a composite score con-
sidering all the essential elements to judge the effectiveness of
treatment in clinical practice, with the maximum of objective
criteria such as the use of a prohibited treatment, endoscopic
dilation, bowel resection, serious adverse event or study with-
drawal. We assessed the primary endpoint at week 24 because it
was one of the two primary endpoints in the pivotal CHARM
trial.28 Moreover, in a similar pilot study including 20 patients
with ileal CD treated with inﬂiximab, the primary endpoint was
at week 26.13 We felt that an earlier assessment would have
been too short to assess the response to adalimumab in patients
with severe intestinal lesions. We also considered that clinical
outcome including treatment efﬁcacy and tolerance was better
indicators for success than radiological changes. Van Assche
et al13 deﬁned an MRE obstructive score and did not ﬁnd any
modiﬁcation of this score at week 26 after anti-TNF (inﬂiximab)
treatment in a cohort of 20 patients with ileal CD.
Approximately two-thirds of the patients reached clinical
success at week 24. We found that the combined treatment with
adalimumab and immunosuppressive agents was associated with
an increased probability of success than adalimumab alone. Such
result should be conﬁrmed in a randomised controlled clinical
trial. The efﬁcacy of combotherapy has been well demonstrated
for inﬂiximab in patients with CD, but is less clear for adalimu-
mab.29 30 We also found that recent and severe obstructive
symptoms were associated with treatment success. In fact, long-
standing and non-severe obstructive scores may reﬂect irrevers-
ible intestinal damage, with a lower probability of success.31 We
found that a total stricture length of <12 cm, an intermediate
dilation of the small bowel proximal to the stricture(s), a
marked enhancement on delayed phase and the absence of
ﬁstula were associated with success. These factors could poten-
tially reﬂect reversible and non-severe strictures. Although
delayed MRE signs are more often due to ﬁbrosis than inﬂam-
mation, only the marked (vs mild–moderate or nil delay)
enhancement was predictive.32 However, marked enhancement
on delayed phase might indicate severe inﬂammation, and a
clear distinction based on standard MRE criteria is not currently
possible.22 26 An intermediate small bowel dilation above the
stricture predicted success as well. The presence of major dila-
tion is usually considered as a late sign and is generally thought
to be due to irreversible intestinal damage. The reason why a
normal intestinal diameter had the same signiﬁcance is unclear,
but may reﬂect more functional symptoms that are non-
responsive to anti-TNFs. Alternatively, some patients with severe
intestinal obstruction may have frequent vomiting and conse-
quently no dilatation above the stricture. Unsurprisingly, the
absence of a ﬁstula, observed in 75% of our population, also
predicted success. CRP was found signiﬁcantly associated with
response in univariate analysis, but not in multivariate.
Moreover, the relation found was on the opposite of what was
expected as low CRP (<5) was associated with high rate of
success. Therefore, what is true for luminal disease is probably
false for stricturing disease, a result that needs to be conﬁrmed.
An important point is whether the medical treatment avoids
or delays surgery in this category of patients. We observed that
51/97 patients (53%) initially treated with adalimumab were
surgery-free after a median follow-up of nearly 4 years.
Nevertheless, it is difﬁcult to ascertain the exact role of adalimu-
mab in this result due to the observational nature of our study
and the absence of a control group.33 Even if we do not claim
that adalimumab has changed the natural history of the disease,
our results may suggest that this could have happened and this
is in accordance with the studies showing that anti-TNFs are
able to reverse strictures, which were thought to be non-
reversible according to the Lemann Index in some patients
with CD.34
The strength of our study is its design based on robust evalu-
ation criteria. The study was adequately powered to detect prog-
nostic factors and it correctly anticipated the success rate.
Prognostic factors associated with success were identiﬁed and
allowed us to build an easy-to-use clinical and imaging prognos-
tic score. The prognostic score dichotomised the cohort into
patients with a score of two points or less who were very
unlikely to respond to adalimumab (6%), and those with a prog-
nostic score of more than two who have a very high (87% with
a prognostic score of four or more) or high (78% with a score
of three or more) probability of success. The internal validity of
this score was conﬁrmed using a bootstrap analysis.
Our study has some limitations. First, it is an uncontrolled,
observational study. However, according to current European
Table 5 Serious adverse events in 97 patients registered during
the study
Variable
From week 0
to week 24
After
week 24 Total
Patients with at least one serious adverse
event, n (%)
31 (32) 39 (40) 70 (72)
Patients with serious adverse events, n
Surgery for Crohn’s disease 18 30 48
Endoscopic dilation 2 2 4
Hospitalisation for Crohn’s disease
complication*
9 4 13
Neurological disorder 0 1 1
Myelodysplasia† 1 0 1
Basal cell carcinoma 1 1 2
Lymphoma 0 1 1
*Occlusive syndrome (seven), severe abdominal pain (three), fever and nausea (one),
severe acute diarrhoea (one) and subacute folliculitis (one).
†The patient died at the age of 82 years, 12 months later of myelodysplasia,
diagnosed 1 month after adalimumab initiation in combotherapy with azathioprine,
initiated 12 months before.
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recommendations21 mentioned earlier, surgery should have
been considered for all patients in this group without knowledge
of any speciﬁc criteria. A controlled trial of anti-TNF versus
surgery is needed to assess which is the best option to preserve
quality of life. Second, the CDOS was empirically constructed
and its operative properties are unknown. Third, MRE was not
interpreted using a central reading system and the inter-
radiologist variation of these items is unknown. However, as
mentioned, all radiologists participated in a speciﬁc meeting
before the launch of the study. Fourth, faecal calprotectin was
measured in <50% of patients at baseline, and statistics could
not be performed for this parameter. Finally, the prognostic
score has not yet been validated in an independent cohort.
In conclusion, adalimumab success was observed at week 24
in about two-thirds of CD patients with symptomatic small
bowel stricture and prolonged in nearly half of the patients in
success at week 24, that is, a third of the whole cohort after a
median follow-up of nearly 4 years. More than half of the
patients initially treated with adalimumab were still free of
surgery 4 years after treatment initiation.
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